Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.32 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29528876 | 0.81 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1AOC3GABRA5 | |
| SCHEMBL13447331 | 0.79 | IKBKB (0.43) | MEN1KMT2AALDH1A1AOC3GABRA5 | |
| SCHEMBL13412495 | 0.79 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1AOC3GABRA5 | |
| SCHEMBL17977280 | 0.78 | MEN1 (0.37) | MEN1KMT2AALDH1A1AOC3GABRA5 | |
| SCHEMBL17717276 | 0.78 | KMT2A (0.44) | MEN1KMT2AALDH1A1AOC3GABRA5 | |
| SCHEMBL29686211 | 0.76 | PLA2G4A (0.44) | MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL4911470 | 0.75 | KMT2A (0.39) | MEN1KMT2AALDH1A1GABRA5GABRB2 | |
| SCHEMBL3512216 | 0.75 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1GABRA5GABRB2 | |
| SCHEMBL2745279 | 0.74 | GABRA5 (0.46) | MEN1KMT2AALDH1A1GABRA5GABRB2 | |
| SCHEMBL5988033 | 0.74 | SMN1; SMN2 (0.49) | MEN1KMT2AALDH1A1GABRA5GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686130-B1 | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents | PFIZER PROD INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20070161666-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC | 2007-07-12 | — | — | US | disclosed |
| US-7192963-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC (US) | 2007-03-20 | — | — | US | disclosed |
| EP-1686130-A1 | Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents | Pfizer Products Incorporated (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1294724-B1 | PYRROLO¬2,3-D|PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS | PFIZER PROD INC (US) | 2006-04-19 | — | — | EP | disclosed |
| US-6962993-B2 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050197349-A1 | Pyrrolo[2,3-D]pyrimidine compounds | PFIZER INC. | 2005-09-08 | — | — | US | disclosed |
| US-6696567-B2 | INHIBITION OF PROTEIN KINASES OR JANUS KINASE 3; TREATING OR PREVENTING ORGAN TRANSPLANT REJECTION, XENO TRANSPLATION, LUPUS, MULTIPLE SCLEROSIS, RHEUMATOID ARTHRITIS, PSORIASIS, TYPE I DIABETES OR VARIOUS DISEASE COMPLICATIONS | PFIZER INC. | 2004-02-24 | — | — | US | disclosed |
| US-20030220353-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-20020068746-A1 | Pyrrolo[2,3-d]pyrimidine compounds | PFIZER INC. | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220353-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, CDK2, JAK3 | MEN1 3323/4885KMT2A 1822/4885ALDH1A1 1719/4885 |
| US-20050197349-A1 | Pyrrolo[2,3-D]pyrimidine compounds | CDK2, CDK3, JAK3 | MEN1 3400/4885KMT2A 1475/4885ALDH1A1 2505/4885 |
| US-20020068746-A1 | Pyrrolo[2,3-d]pyrimidine compounds | JAK1, CDK2, JAK3 | MEN1 3323/4885KMT2A 1822/4885ALDH1A1 1719/4885 |
| US-20070161666-A1 | Pyrrolo[2,3-d]pyrimidine compounds | CDK2, CDK3, JAK3 | MEN1 3400/4885KMT2A 1475/4885ALDH1A1 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.